Food Allergy Science Initiative FASI

Boston was glowing blue + green for FASI tonight. 💙💚

We kicked off by bringing our Principal Investigators together for a day of science, collaboration, and reflection—and an evening celebrating the researchers who have powered ten years of discovery.

Seeing the Prudential Center lit in FASI colors was a pretty incredible way to mark the moment.

Ten years of questions, discoveries, and progress. And we’re just getting started.

Just 1 day to go until FASI-10.

Tomorrow, our community comes together to celebrate 10 years of discovery, collaboration, and progress in food allergy research—and to look ahead to what comes next.

As we get ready to welcome everyone, we want to once again thank the sponsors who helped make this milestone event possible.

A special thank you to our Innovator Sponsors, InBio and DBV Technologies, for their generous support.

We’re also deeply grateful to our community and in-kind sponsors: Citizens Private Bank, Genentech, Regeneron, Withum, Curia, evitria AG, Mabylon AG, Spectrus, ARS Pharmaceuticals, ALK, Broad Institute of MIT and Harvard, Free2b Foods, Partake Foods, Tiny Health, That’s it., Vermont Nut Free Chocolates, Gayle M. Rigione / Allergy Force, Lisa Shapiro Strovink / AllerFund Ventures, and Patty Howard / Be Like Timmy Foundation.

Thank you for being part of FASI-10. We cannot wait to see you at the Summit.

Four days to go.

The FASI-10 Summit is almost here—bringing together scientists, clinicians, industry leaders, partners, and families to reflect on a decade of discovery and look ahead to what comes next.

And this year, “what comes next” includes something new.

We’ll be sharing a major announcement at FASI-10—one designed to help move the science we’ve built toward the pathways patients need.

Stay tuned. More on October 5–7.

We are thrilled to announce a partnership with InBio, a globally trusted provider of high-purity materials that power better research and faster progress.

What does this mean for FASI?
🔑 Reliable channel for materials that are key to our translational work
🔬 Broader research capabilities and preclinical expertise
🤝 Aligns with FASI’s commitment to scientific rigor

We are excited to see what this mutually beneficial partnership yields and what we can accomplish, together, in pursuit of breakthrough discoveries that could transform the lives of millions of people affected by food allergy.

Read more here: https://foodallergyscience.org/fasi-and-inbio-partner-to-accelerate-food-allergy-research/

For 10 years, visionary leaders have helped shape the future of food allergy research. Today, we are honored to spotlight one of our board members, Eric Edwards, M.D., Ph.D., whose lived experience fuels the passion for progress. Dr. Edward's voice represents both a personal journey and scientific expertise that continue to drive meaningful change in FASI's work in food allergy research.

We are grateful for leadership that pushes beyond awareness and toward real answers and real treatments, because answers matter.

What does a year of food allergy science look like?

In FY2026, FASI deployed $5.4 million in research funding, awarded 17 new research grants, and continued supporting science that is changing how we understand food allergy.

This year's work spans the full research continuum: uncovering mechanisms that drive severe allergic reactions, investigating how microbial exposure shapes immunity, mapping interactions between the gut, nervous system and immune system, contributing to large-scale studies of how allergic disease begins, and investing in clinical research designed to move new ideas closer to patients.

These advances are possible because of an extraordinary community of scientists, clinicians, donors, advocates, patients and families.

This progress belongs to all of you.

Explore highlights from our 2025–2026 Year in Review, and read the full FY26 Impact Report here: https://foodallergyscience.org/financials/

Around the country, pockets of Alpha Gal Syndrome are on the rise. The Hamptons are one of the hardest hit areas nationally, with more than 3,700 suspected cases in the county in the CDC’s latest five-year report.

In the Southampton Press, our co-founder and executive chair Christine Olsen reflects on what those new allergy sufferers may be experiencing, not just in their physical symptoms but in the uncertainty they feel.

But if the war on cancer tells us anything, it’s that breakthroughs and better outcomes are possible when there is enough collective will to demand them.

Read the piece: https://www.27east.com/east-hampton-press/opinion/columns/article_3dc9609e-86f1-4f08-8997-60a896367d85.html

Not all immune cells respond to treatment the same way.

Two people can receive the same food allergy treatment and experience very different outcomes.

FASI Researchers developed a way to track distinct groups of reactive T cells during oral immunotherapy, or OIT. In a small study, they found that treatment quieted allergy-related activity in some immune cell populations more than others.

People with better outcomes showed stronger suppression of one allergy-associated group of T cells, while broader inflammatory signals persisted in people with less successful outcomes.

These findings are an early research clue—not yet a test---that can predict how someone will respond to OIT. But they point toward a more detailed understanding of treatment response and, ultimately, the possibility of more precise approaches to food allergy treatment.

Swipe through Big Discovery #10 to learn more.